Alterations of the oral microbiota in mild Alzheimer's disease and the appropriate application of chlorhexidine gluconate
- PMID: 40810098
- PMCID: PMC12344254
- DOI: 10.1016/j.jarlif.2025.100024
Alterations of the oral microbiota in mild Alzheimer's disease and the appropriate application of chlorhexidine gluconate
Abstract
Objective: This study investigated the effect of 0.2 % chlorhexidine gluconate on oral microbiota dysbiosis in Alzheimer's disease (AD) and explored potential links between oral microbiota and cognition, offering new insights into its role in AD treatment.
Study design: We assessed the impact of 0.2 % chlorhexidine gluconate on the oral microbiota of patients with AD. One hundred patients were divided into two groups based on oral health score (using a cut-off of 8). Subgingival plaque samples were analyzed using 16S rRNA sequencing; no significant differences in bacterial composition were observed between groups at baseline.
Results: Poor oral health correlated with higher oral health scores (P = 0.000), fewer teeth (P = 0.002), lower cognitive levels (P = 0.048), and a higher proportion of patients with diabetes (P = 0.032). After 24 weeks of treatment with 0.2 % chlorhexidine gluconate in a randomized controlled trial, subgingival plaques from 66 patients showed changes in Porphyromonas, Filifactor, Desulfobulbus, Anaeroglobus, Pyramidobacter, Mycoplasma, Dialister, Fretibacterium, and Tannerella (P < 0.05). Treponema and Porphyromonas gingivalis were identified as potential interventional targets.
Conclusion: Chlorhexidine gluconate effectively alters oral flora, reducing harmful bacteria. Targeting specific microbiota disturbances may offer a promising strategy to delay AD onset or slow its progression.
Trial registration: This research was registered with the Chinese Clinical Trial Registry (ChiCTR; Reference: ChiCTR2000032876). Registered: 14th of May 2020; http://www.chictr.org.cn/showprojen.aspx?proj=53555.
Keywords: 16S rRNA; Alzheimer’s disease; Chlorhexidine gluconate; Neuroinflammation; Oral microbiota.
© 2025 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures



Similar articles
-
Chlorhexidine mouthrinse as an adjunctive treatment for gingival health.Cochrane Database Syst Rev. 2017 Mar 31;3(3):CD008676. doi: 10.1002/14651858.CD008676.pub2. Cochrane Database Syst Rev. 2017. PMID: 28362061 Free PMC article.
-
Pharmacotherapies for sleep disturbances in Alzheimer's disease.Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178. doi: 10.1002/14651858.CD009178.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Nov 16;11:CD009178. doi: 10.1002/14651858.CD009178.pub3. PMID: 24659320 Updated.
-
Donepezil for dementia due to Alzheimer's disease.Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article.
-
Chlorhexidine treatment for the prevention of dental caries in children and adolescents.Cochrane Database Syst Rev. 2015 Apr 13;2015(4):CD008457. doi: 10.1002/14651858.CD008457.pub2. Cochrane Database Syst Rev. 2015. PMID: 25867816 Free PMC article.
-
Pharmacotherapies for sleep disturbances in dementia.Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Nov 15;11:CD009178. doi: 10.1002/14651858.CD009178.pub4. PMID: 27851868 Free PMC article. Updated.
References
-
- Alzheimer's disease facts and figures. Alzheimer Dement. 2024;2024
-
- Chenshuang L., Lingling W., Lieyun D., et al. Determinants and inequities in healthy working life expectancy in China. Nat Med. 2024;(0) - PubMed
LinkOut - more resources
Full Text Sources